DexCom (DXCM)
(Real Time Quote from BATS)
$70.36 USD
-0.07 (-0.10%)
Updated Sep 23, 2024 02:58 PM ET
4-Sell of 5 4
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
DXCM 70.36 -0.07(-0.10%)
Will DXCM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DXCM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DXCM
Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe
DexCom Stock May Gain on Expanded Reach After Stelo's US Launch
DXCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
DexCom's (DXCM) G7 CGM Coverage Expanded for Quebec Residents
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity
Other News for DXCM
Dexcom, Beyond Type 2 and Retta Establish National Glucose Awareness Week to Close the Glucose Knowledge Gap
Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)
‘No pain, no gain,’ just look at stocks that jumped nearly 1,000% in a 5-year time span
DexCom put volume heavy and directionally bearish
DexCom: Investors Discounting Long CGM Growth Runway